| Ytd | 47.06% | |
| 1y | 51.73% |
| Open | 4.97 | Prev Close | 5.25 | Low | 4.97 | High | 5.27 | Mkt Cap | 420.14M |
| Vol | 264.99K | Avg Vol | 365.60K | EPS | -2.11 | P/E | -2.49 | Forward P/E | -2.12 |
| Beta | 0.30 | Short Ratio | 14.25 | Inst. Own | 71.14% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 4.63 | 200-d Avg | 4.39 | 1yr Est | 7.40 |
AVIR News
BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company
Bemnifosbuvir/Ruzasvir (BEM/RZR) Achieved its Primary Endpoint of Statistical Non-inferiority Compar
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical
Phase 1 Study Designed to Evaluate the Safety, Tolerability and Pharmacokinetics of AT-587 in Health
Gainers Q32 Bio (NASDAQ:QTTB) stock moved upwards by 44.4% to $16.19 during Friday's after-mark
Topline Phase 3 Results from C-FORWARD Expected Around Year-End 2026 More Than 880 HCV Treatment-Naï
Atea Pharmaceuticals (AVIR) might move higher on growing optimism about its earnings prospects, whic
Here is how Atea Pharmaceuticals, Inc. (AVIR) and Design Therapeutics, Inc. (DSGN) have performed co
Atea Pharmaceuticals, Inc. receives a buy rating ahead of pivotal phase 3 BEM/RZR hepatitis C data e
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company)
Atea Pharmaceuticals (AVIR) has become technically an oversold stock now, which implies exhaustion o
BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company)
Atea Pharmaceuticals, Inc. (AVIR) Q1 2026 Earnings Call Transcript
Atea Pharmaceuticals NASDAQ: AVIR said it remains on track for two key Phase 3 hepatitis C readouts
C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company)
Trevi Therapeutics (NASDAQ: TRVI - Get Free Report) and Atea Pharmaceuticals (NASDAQ: AVIR - Get Fre
Atea Pharmaceuticals (NASDAQ: AVIR) outlined progress in its hepatitis C (HCV) late-stage developmen
Atea Pharmaceuticals, Inc. (AVIR) Q4 2025 Earnings Call Transcript
Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Result
BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company
Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus Initiation of Pha
Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its
On Monday, 369 companies set new 52-week lows.
Companies Reporting Before The Bell • Warner Music Gr (NASDAQ:WMG) is likely to report quarterly ea
On Friday, 469 companies hit new 52-week lows.
On Tuesday, 838 companies hit new 52-week lows.
During Monday's trading, 528 companies set new 52-week lows.
On Friday, 1043 companies hit new 52-week lows.
40 Biggest Movers From Yesterday
35 Stocks Moving In Monday's Mid-Day Session
30 Stocks Moving In Monday's Pre-Market Session